Rights and permissions
About this article
Cite this article
Certolizumab pegol wins as third-line therapy for Crohn's disease. Pharmacoecon. Outcomes News 639, 8 (2011). https://doi.org/10.2165/00151234-201106390-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106390-00017